

August 5, 2024
Web Announcement 3406

Drug Use Review (DUR) Board approves changes effective August 5, 2024

The Nevada Medicaid Drug Use Review (DUR) Board met on April 18, 2024, and voted to adopt the following changes to Pharmacy Point-of-Sale (POS) criteria, effective August 5, 2024:

Drug Class/Program	Background and Explanation of Policy Changes, Clarifications and Updates
Sickle Cell	Addition of two new drugs – Lyfgenia® and Casgevy®
Wainua® (eplontersen)	Addition of new drug
Xgeva® (denosumab)	Adoption of prior authorization criteria and/or quantity limits
Ocrevus® (ocrelizumab)	Adoption of prior authorization criteria and/or quantity limits

Prior Authorization forms may be found on the pharmacy webpage:
<https://nevadamedicaid.magellanrx.com/provider/forms> (pharmacy/point-of-sale)